- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01919554
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents
January 3, 2014 updated by: Stallergenes Greer
Investigation of the Safety and Tolerability of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents With House Dust Mite-associated Allergic Rhinitis
The purpose of this study is to investigate the safety and tolerability of different doses of sublingual tablets of house dust mite (HDM) allergen extracts in adolescents with house dust mite-associated allergic rhinitis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
37
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Mississauga, Ontario, Canada, L4W 1N2
- Inflamax Research Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 17 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent from patient and parent(s)/legal representative.
- Male or female patient from 12 to 17 years.
- Diagnosed rhinitis with medical history consistent with HDM-induced allergic rhinitis for at least 1 year before visit 1
- Positive Skin Prick Test to House Dust Mites(HDM)and HDM-specific IgE serum value ≥ 0.7 kUnit/L.
- Concommittant controlled asthma allowed up to GINA 1 or 2 treatment step
- Spirometry with best FEV1 > 80% of predicted FEV1.
Exclusion Criteria:
- Patient with a nasal or oral disease that could interfere with the safety assessments
- Patient has undergone recent nasal surgery
- Patient with asthma receiving therapy consistent with GINA (Global INitiative for Asthama) treatment step 3, 4, or 5.
- Patient with partially controlled or uncontrolled asthma
- Patient with a past or current disease, which as judged by the Investigator, may affect the patient's participation in or the outcome of this study.
- Female patient pregnant or breast-feeding/lactating.
- Female patient of childbearing potential planning a pregnancy during this trial or not using a medically accepted contraceptive method.
- Patient treated with beta-blockers, tricyclic antidepressants or monoamine oxidase inhibitors (MAOIs).
- Patient who received allergy specific immunotherapy for house dust mites for more than 1 month in the 5 years before screening or who is currently receiving immunotherapy with any allergen.
- patient with a history of anaphylaxis
- patient having participated in any clinical study within the 12 weeks before visit 1
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo Sub Lingual Immunotherapy Tablets (SLIT)
Placebo tablets Matching the HDM allergen extract Sub Lingual Immunotherapy Tablets
|
|
EXPERIMENTAL: SLIT of HDM allergen extracts
Sublingual Immunotherapy Tablets of House Dust Mite allergen extracts
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability evaluated on treatment emergent adverse events
Time Frame: 10 dosing treatment days
|
Safety, tolerability evaluated on treatment adverse events and safety laboratory testings
|
10 dosing treatment days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment emergent Serious Adverse Events
Time Frame: 10 dosing treatment days
|
Treatment emergent Serious Adverse Events
|
10 dosing treatment days
|
Adverse Events leading to study withdrawal
Time Frame: 10 dosing treatment days
|
Incidence of adverse events leading to study withdrawal
|
10 dosing treatment days
|
Spirometry parameters
Time Frame: 10 dosing treatment days
|
Change in spirometry parameters between selection visit and last treatment day
|
10 dosing treatment days
|
Safety laboratory testings
Time Frame: 10 dosing treatment days
|
Change in safety laboratory testing values between selection visit and last treatment day
|
10 dosing treatment days
|
12 lead ECG parameters
Time Frame: 10 dosing treatment days
|
Change in ECG parameters between selection visit and last treatment day
|
10 dosing treatment days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2013
Primary Completion (ACTUAL)
September 1, 2013
Study Completion (ACTUAL)
September 1, 2013
Study Registration Dates
First Submitted
August 2, 2013
First Submitted That Met QC Criteria
August 6, 2013
First Posted (ESTIMATE)
August 9, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
January 6, 2014
Last Update Submitted That Met QC Criteria
January 3, 2014
Last Verified
January 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VO73.13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on House Dust Mite Allergic Rhinitis
-
Inmunotek S.L.BioClever 2005 S.L.; NTS hub S.LTerminatedEfficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/RhinoconjunctivitisPerennial Allergic Rhinitis | Allergic Rhinoconjunctivitis | House Dust Mite Allergy | Pollen AllergySpain
-
Inmunotek S.L.LAT Research; Xolomon Tree S.L.Not yet recruitingAllergic Rhinitis | Allergic Asthma | Allergic Rhinoconjunctivitis | Allergy to House Dust MiteArgentina
-
RAPHASEnrolling by invitationRhinitis, Allergic | Mite Allergy | House Dust Mite RhinitisKorea, Republic of
-
Eye & ENT Hospital of Fudan UniversityNot yet recruitingAllergic Rhinitis Due to House Dust Mite
-
Universitaire Ziekenhuizen KU LeuvenTerminated
-
Cytos Biotechnology AGCompletedHouse Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis
-
Gadjah Mada UniversityEnrolling by invitationAllergic Rhinitis | Allergic Rhinitis Due to House Dust MiteIndonesia
-
ALK-Abelló A/SActive, not recruitingAllergic Rhinitis Due to Dermatophagoides Farinae | Allergic Rhinitis Due to Dermatophagoides Pteronyssinus | Allergic Rhinitis Due to House Dust MiteSpain, Russian Federation, United States, Poland, Bulgaria, Canada, France, Germany, Lithuania, Slovakia, Ukraine
-
Universitaire Ziekenhuizen KU LeuvenUnknownAllergic Rhinitis | House Dust Mite AllergyBelgium
-
ASIT Biotech S.A.CompletedHouse Dust Mite AllergyGermany
Clinical Trials on SLIT tablets of HDM allergen extracts
-
Stallergenes GreerCompletedAsthma | House Dust Mite AllergyFrance, Germany, Poland
-
Stallergenes GreerCompletedAsthma | House Dust Mite AllergyFrance
-
University of SouthamptonIsle of Wight NHS TrustCompletedAsthma | Immunotherapy | Allergy and ImmunologyUnited Kingdom
-
Albert Einstein College of MedicineJacobi Medical CenterCompleted
-
AlyatecCompletedAllergy | Allergic Asthma | Allergy to House DustFrance
-
Gachon University Gil Medical CenterThermo Fisher Scientific, IncTerminatedAllergic RhinitisKorea, Republic of
-
Casa Espirita Terra de IsmaelFundação de Amparo à Pesquisa do Estado de São PauloCompletedAtopic Dermatitis | Effects of ImmunotherapyBrazil
-
Schwabe-Wenex International LtdCompleted
-
National Institute of Allergy and Infectious Diseases...Regeneron Pharmaceuticals; PPD; Rho Federal Systems Division, Inc.; ALK-Abelló A/S and other collaboratorsActive, not recruitingGrass Pollen Allergy | Allergic RhinoconjunctivitisUnited Kingdom
-
Benjamin MedoffNational Institutes of Health (NIH); U.S. Army Medical Research and Development...Recruiting